Profile data is unavailable for this security.
About the company
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
- Revenue in GBP (TTM)1.78m
- Net income in GBP-14.41m
- Incorporated2020
- Employees--
- Location4Basebio PLC25 Norman Way, OverCAMBRIDGE CB24 5QEUnited KingdomGBR
- Phone+44 122 396 7943
- Websitehttps://www.4basebio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sareum Holdings Plc | 0.00 | -4.44m | 21.40m | 5.00 | -- | 9.15 | -- | -- | -0.0365 | -0.0365 | 0.00 | 0.0169 | 0.00 | -- | -- | 0.00 | -126.85 | -93.37 | -202.14 | -118.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.77 | -- | -- | -- |
| Skinbiotherapeutics PLC | 4.64m | -696.25k | 24.15m | 41.00 | -- | 2.56 | -- | 5.21 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Arecor Therapeutics PLC | 5.06m | -8.10m | 27.37m | 37.00 | -- | 9.58 | -- | 5.41 | -0.2208 | -0.2208 | 0.1368 | 0.0756 | 0.6482 | 18.58 | 1.93 | 136,783.80 | -103.79 | -53.69 | -187.88 | -68.26 | -2.45 | -- | -160.13 | -248.39 | 2.00 | -- | 0.0571 | -- | 10.50 | -- | -19.66 | -- | -- | -- |
| Poolbeg Pharma PLC | 0.00 | -5.71m | 31.37m | 10.00 | -- | 2.63 | -- | -- | -0.0114 | -0.0114 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -45.01 | -- | -46.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -47.29 | -- | -- | -- |
| ImmuPharma PLC | 0.00 | -3.93m | 38.91m | 6.00 | -- | 114.88 | -- | -- | -0.0089 | -0.0089 | 0.00 | 0.0007 | 0.00 | -- | -- | 0.00 | -139.44 | -89.81 | -259.88 | -121.17 | -- | -- | -- | -9,895.75 | -- | -2.76 | 0.00 | -- | -- | -- | 15.00 | -- | -56.60 | -- |
| hVIVO PLC | 51.28m | 5.28m | 55.21m | 301.00 | 10.43 | 1.26 | 6.17 | 1.08 | 0.0077 | 0.0077 | 0.0748 | 0.0635 | 0.5914 | -- | 3.32 | 170,362.10 | 6.09 | 5.51 | 9.53 | 10.35 | -- | -- | 10.30 | 6.73 | 1.53 | -- | 0.2521 | 66.99 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.98m | 61.65m | 25.00 | -- | -- | -- | -- | -0.2526 | -0.2526 | 0.00 | -0.1354 | 0.00 | -- | -- | 0.00 | -119.80 | -227.46 | -304.25 | -1,738.54 | -- | -- | -- | -- | -- | -1.65 | 3.64 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.81m | 65.22m | 16.00 | -- | -- | -- | -- | -2.21 | -2.21 | 0.00 | -0.1089 | 0.00 | -- | -- | 0.00 | -169.60 | -87.04 | -210.76 | -102.48 | -- | -- | -- | -- | -- | -2.14 | 1.33 | -- | -- | -- | 16.01 | -- | 2.20 | -- |
| Bioventix PLC | 13.12m | 7.58m | 79.68m | 16.00 | 10.57 | 6.90 | 10.38 | 6.08 | 1.44 | 1.44 | 2.49 | 2.21 | 0.9864 | 1.84 | 2.10 | 819,741.90 | 57.04 | 58.17 | 64.40 | 64.19 | 90.86 | 92.79 | 57.83 | 61.84 | 8.65 | -- | 0.00 | 105.34 | -3.61 | 4.92 | -6.33 | 1.04 | -43.71 | 11.26 |
| 4Basebio PLC | 1.78m | -14.41m | 90.12m | -- | -- | 4.73 | -- | 50.66 | -0.9923 | -0.9923 | 0.1226 | 1.23 | 0.0729 | 1.54 | 21.56 | -- | -59.05 | -36.81 | -64.81 | -40.98 | 61.55 | 69.88 | -809.95 | -1,160.83 | 11.15 | -95.30 | 0.4485 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Scancell Holdings Plc | 4.71m | -5.51m | 135.95m | 60.00 | -- | -- | -- | 28.86 | -0.0053 | -0.0053 | 0.0047 | -0.0081 | 0.2946 | -- | 8.26 | 78,516.66 | -34.46 | -33.29 | -- | -44.23 | 94.95 | -- | -116.98 | -502.03 | -- | -- | 2.07 | -- | -- | -- | -109.46 | -- | 124.48 | -- |
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 30 Sep 2025 | 1.96m | 12.62% |
| Hargreaves Lansdown Fund Managers Ltd.as of 02 Jan 2026 | 161.00k | 1.04% |
| Aramea Asset Management AGas of 30 Jun 2022 | 143.33k | 0.92% |
| Bankinter Gesti�n de Activos SA SGIICas of 02 Jan 2026 | 123.00k | 0.79% |
| KW Investment Management Ltd.as of 02 Jan 2026 | 64.00k | 0.41% |
| HSBC Bank Plc (Market-Maker)as of 02 Jan 2026 | 32.00k | 0.21% |
| Rathbones Investment Management Ltd.as of 02 Jan 2026 | 30.00k | 0.19% |
| DWS Investment GmbHas of 28 Nov 2025 | 13.36k | 0.09% |
| Renta 4 Sociedad de Valores SAas of 02 Jan 2026 | 13.00k | 0.08% |
| Winterflood Securities Ltd (Market-Maker)as of 02 Jan 2026 | 8.00k | 0.05% |
